Caproic acid
|
Basic information |
| Metabolite name | Caproic acid |
 | HMDB0000535 |
 |
C01585 |
 |
8892 |
| Synonyms | hexanoic acid; |
| No. of studies | 13 |
|
Basic information |
| Metabolite name | Caproic acid |
| HMDB0000535 |
|
C01585 |
|
8892 |
| Synonyms | hexanoic acid; |
| No. of studies | 13 |
|
Relationship between Caproic acid and depression (count: 13) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M003 | Type1 | day 27 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M077 | Type1 | non-weaned group vs. weaned group | Urine | Wistar rat | Down |
| Study M077 | Type1 | non-weaned FST group vs. weaned FST group | Urine | Wistar rat | Down |
| Study M1003 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M1003 | Type2 | CUMS + high dose of alcohol-soluble polysaccharides group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M1003 | Type2 | CUMS + Morinda officinalis oligosaccharide group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M1003 | Type2 | CUMS + low dose of alcohol-soluble polysaccharides group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1027 | Type1 | CUMS group vs. control group | Faece | Wistar rat | Down |
| Study M1027 | Type2 | CUMS + fluoxetine group vs. CUMS group | Faece | Wistar rat | Up |
| Study M712 | Type1 | depression group vs. control group | Hippocampus | Cynomolgus monkey | Up |
| Study M804 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M804 | Type2 | CUMS + fluoxetine group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M804 | Type2 | CUMS + middle dose of WYJYD group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M804 | Type2 | CUMS + high dose of WYJYD group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M872 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M872 | Type2 | CUMS + rifaximin group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M901 | Type1 | LPS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M901 | Type2 | LPS + Schisandrin group vs. LPS group | Faece | C57BL/6 mouse | Up |
| Study M919 | Type1 | chronic cerebral hypoperfusion group vs. sham group | Hippocampus | Sprague-Dawley rat | Up |
| Study M967 | Type1 | bilateral common carotid artery occlusion group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M999 | Type2 | CRS + paroxetine group vs. CRS group | Faece | C57BL/6J mouse | Up |
| Study M999 | Type2 | CRS + high dose of neoagaro-oligosaccharides group vs. CRS group | Faece | C57BL/6J mouse | Up |